In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Optical coherence tomography for stent insertion in complex cases shows mixed efficacy

ILUMIEN IV trial presented in a Hot Line session today at ESC Congress 2023

Interventional Cardiology and Cardiovascular Surgery


Amsterdam, Netherlands – 27 Aug 2023: Optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) leads to a larger minimum stent area but does not reduce the two-year rate of target vessel failure compared with angiography-guided PCI, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1 Stent thrombosis was significantly reduced with OCT-guided PCI.

Previous randomised trials have demonstrated improved clinical outcomes with intravascular imaging-guided PCI compared with angiography guidance alone, including in complex patients.2-4 These findings have led to a Class IIa recommendation in ESC Guidelines.5 The ILUMIEN IV trial investigated whether OCT-guided PCI is superior to angiography-guided PCI for minimum stent area and target vessel failure in complex patients and lesions.

The trial enrolled patients with medication-treated diabetes and/or complex lesions (defined as non-ST-segment elevation myocardial infarction [NSTEMI], late-presenting ST-segment elevation myocardial infarction [STEMI; >24 hours], stent length ≥28 mm, severe calcification, two-stent bifurcation, in-stent restenosis or chronic total occlusion)  at 80 sites in 18 countries. The investigators chose to include only complex patients and complex lesions as these patients were considered the most likely to gain the benefit of OCT guidance. Patients were randomised in a 1:1 ratio to OCT-guided PCI or angiography-guided PCI. Blinded OCT was performed after PCI in the angiography group to enable assessment of the first co-primary endpoint and other differences between the two treatment arms. Patients and post-procedure research personnel were blinded to treatment assignment.

The co-primary endpoints were 1) the post-PCI minimum stent area (an independent predictor of future adverse events after drug-eluting stent implantation6,7) assessed by OCT and 2) the two-year rate of target vessel failure, defined as a composite of cardiac death, target vessel myocardial infarction or ischaemia-driven target vessel revascularisation. Safety was also assessed.

The trial included 2,487 patients, of whom 1,233 received OCT-guided PCI and 1,254 received angiography-guided PCI. The mean age of participants was 65.6 years and 22.6% were women. For efficacy, the minimum stent area achieved was larger in the OCT-guided group than in the angiography-guided group (5.72 ± 2.04 vs. 5.36 ± 1.87 mm2; difference 0.36 mm2, 95% confidence interval [CI] 0.21 to 0.51; p<0.001). Target vessel failure within two years occurred in 88 OCT-guided patients and 99 angiography-guided patients (Kaplan-Meier estimated rates 7.4% vs. 8.2% respectively; hazard ratio [HR] 0.90; 95% CI 0.67 to 1.19; p=0.45).

Regarding safety, there were fewer angiographic complications with the OCT guidance strategy. In addition to the larger minimum stent area, OCT guidance resulted in fewer cases of major dissection, malapposition, tissue protrusion and untreated reference segment disease. Stent thrombosis within two years occurred in 6 (0.5%) OCT-guided patients and in 17 (1.4%) angiography-guided patients (HR, 0.36; 95% CI, 0.14 to 0.91). The number of cardiac deaths and myocardial infarctions were fewer in the OCT arm, although these differences were not statistically significant.

Study author Dr. Ziad Ali of St. Francis Hospital, Roslyn, US said: “OCT-guided PCI led to a larger minimum stent area, enhanced the safety of the PCI procedure and resulted in a nearly two-thirds reduction in stent thrombosis during two-year follow-up. However, in this trial OCT guidance did not reduce the two-year rate of target vessel failure compared with angiography-guided PCI because of a low and nearly identical rate of target vessel revascularisation in the OCT-guided and angiography-guided PCI arms.”

 

ENDS

Notes to editor

ESC Press Office
Tel: +33 (0)6 61 40 18 84

Email: press@escardio.org

The hashtag for ESC Congress 2023 is #ESCCongress

Follow us on Twitter @ESCardioNews 

 

Funding: Funded by Abbott.

 

Disclosures: Institutional grant support from Abbott, Abiomed, Acist Medical, Boston Scientific, Cardiovascular Systems Inc, Medtronic Inc, National Institute of Health, Opsens Medical, Philips, Teleflex. Consulting fees from Astra Zeneca, Philips, Shockwave. Equity in Elucid, Spectrawave, Shockwave, VitalConnect. 

 

References and notes

1ILUMIEN IV will be discussed during Hot Line 4 on Sunday 27 August at 08:30 to 10:00 CEST in room Amsterdam.

2Hong SJ, Kim BK, Shin DH, et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: The IVUS-XPL randomized clinical trial. JAMA. 2015;314:2155-2163.

3Zhang J, Gao X, Kan J, et al. Intravascular ultrasound versus angiography-guided drug-eluting stent implantation: The ULTIMATE trial. J Am Coll Cardiol. 2018;72:3126-3137.

4Lee JM, Choi KH, Song YB, et al. Intravascular imaging-guided or angiography-guided complex PCI. N Engl J Med. 2023;388:1668-1679.

5Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.

6Soeda T, Uemura S, Park SJ, et al. Incidence and clinical significance of poststent optical coherence tomography findings: One-year follow-up study from a multicenter registry. Circulation. 2015;132:1020-1029.

7Katagiri Y, De Maria GL, Kogame N, et al. Impact of post-procedural minimal stent area on 2-year clinical outcomes in the SYNTAX II trial. Catheter Cardiovasc Interv. 2019;93:E225-E234.

 

About ESC Congress 2023

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.

 

About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.